Ambrisentan

Drug Profile

Ambrisentan

Alternative Names: BSF 208075; GSK 1325760; GSK1325760A; Letairis; Volibris

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott GmbH & Co. KG
  • Developer Gilead Sciences; GlaxoSmithKline
  • Class Phenylpropionates; Pyridazines; Small molecules
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension; Pulmonary hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension
  • Phase III Pulmonary hypertension
  • Discontinued Idiopathic pulmonary fibrosis

Most Recent Events

  • 01 Jan 2017 Gilead Sciences settles the patent litigation with Watson Laboratories (Gilead Sciences 10-K, February 2017)
  • 25 Nov 2015 Registered for Pulmonary arterial hypertension (Combination therapy, First-line therapy) in European Union (PO)
  • 25 Nov 2015 Registered for Pulmonary arterial hypertension (Combination therapy, First-line therapy) in Norway, Iceland, Liechtenstein (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top